DANIEL TAN: Open Payments
NPI 1811193766 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$36,444 in 252 payments from 16 companies in 2025. Trend: 2023 $33,054 · 2024 $34,640 · 2025 $36,444
Honoraria: $21,600Food & beverage: $6,796Travel & lodging: $5,186Speaker / faculty: $2,863
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 59 | $28,140 |
| Noven Therapeutics, LLC | 11 | $3,072 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $837 |
| E.R. Squibb & Sons, L.L.C. | 19 | $694 |
| Otsuka America Pharmaceutical, Inc. | 22 | $670 |
| Vanda Pharmaceuticals Inc. | 20 | $616 |
| Axsome Therapeutics, Inc. | 16 | $510 |
| Corium, LLC | 20 | $437 |
| Lundbeck LLC | 16 | $410 |
| Tris Pharma Inc | 14 | $389 |
Products named: Qelbree, Xelstrym, REXULTI, CAPLYTA, COBENFY, FANAPT, Auvelity, Azstarys.
Industry payments across TX — which companies pay providers there.
